Myriad Genetics Inc. and Pfizer Inc. announced a commercialization plan under an existing companion diagnostic agreement, in which Myriad is pursuing FDA approval for its BRACAnalysis CDx to be used as a companion diagnostic with Pfizer’s investigational PARP inhibitor, talazoparib.
With the fiscal year drawing to a close, grant funding from NCI is picking up speed, offering a glimmer of hope to cancer researchers who are beginning to feel cautiously optimistic about the road ahead.
